A Multicenter Cohort Study of the Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
Phase of Trial: Phase IV
Latest Information Update: 03 Oct 2019
Price : $35 *
At a glance
- Drugs Micafungin (Primary) ; Antifungals
- Indications Mycoses
- Focus Adverse reactions
- Acronyms MYCOS
- Sponsors Astellas Pharma Europe Ltd
- 03 Oct 2019 Results published in the Journal of Antimicrobial Chemotherapy
- 04 Mar 2019 Status changed from active, no longer recruiting to completed.
- 01 Sep 2017 Planned End Date changed from 1 Nov 2019 to 1 Jan 2020.